HANGZHOU, China, Dec. 16, 2025 /PRNewswire/ -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human clinical study at The Second Affiliated Hospital, School of Medicine, Zhejiang University ("SAHZU"). This milestone marks the first clinical evaluation of the device's safety and performance in patients.
PVAD supports the cardiac output via a percutaneously implanted pump, reduces the load of left ventricle, relieves heart failure symptoms, and bridges to transplantation or recovery. It also delivers temporary hemodynamic support during Complex Higher-risk Indicated Patients Percutaneous Coronary Intervention (CHIP PCI) procedures by augmenting cardiac output, preserving organ perfusion, and stabilizing hemodynamics for safe intervention. While over 60,000 pVAD procedures are performed globally each year, no pVAD product has been approved in China yet, underscoring the significant unmet medical need.
OpusOne™ features an ultra-low profile down to 8F, external durable motor placement, and an all-new design of foldable, self-expanding impeller, capable of delivering 4–5 L/min of average flow with peak flows exceeding 7 L/min. Notably, this ultra-compact device integrates invasive blood pressure monitoring and patented perfusion purification system, enabling migration detection alerts while preventing wear particles from entering the patient's body. With high durability, enhanced reliability, OpusOne™ simplifies clinical procedures, improves patient accessibility, and emerges as a highly competitive pVAD - rivaling Abiomed's Impella, Magenta's Elevate, and Supira's pVAD systems.
"Enginprime's OpusOneTM exemplified a promising approach to temporary ventricular support—especially for high-risk patients who can benefit from enhanced hemodynamic stability. Co-developed by the interventional cardiologists and Enginprime, this promising solution is tailored to address unmet clinical needs." said the study's lead investigator Jian'an Wang, MD,PhD, Director of the Cardiac Center at SAHZU. "I am impressed by its ability to achieve high flow with such a low-profile design. OpusOneTM's optimization of access and positioning options increases procedural safety."
Co-investigator of the study, Jun Jiang, MD, PhD, Executive Associate Director of the Department of Cardiology at SAHZU added, "We are pleased to perform the first procedure with OpusOneTM, seeing the patient's chest tightness was significantly alleviated. Its robust initial performance marks a meaningful advancement in circulatory support and great potential for expanding patient eligibility."
"The development of OpusOneTM reflects our mission to bring globally competitive, exceptional performance and high reliability, cost-effective next-generation circulatory support products to patients who need them most," said the CEO of Enginprime. "We look forward to advancing this innovative device rapidly through further clinical validations."
About Enginprime Medical Inc.
Enginprime was established in 2023 and incubated under majority ownership by Voyagers Capital, leveraging cross-disciplinary engineering capabilities, systems integration expertise, and advanced manufacturing methodologies. OpusOne™ is the company's first flagship medical device platform and reflects Voyagers' long-term commitment to supporting breakthrough healthcare technologies.
About Voyagers Capital
Voyagers Capital is a leading healthcare venture capital firm focused on investing in groundbreaking biotech and medtech innovation. By leveraging our expertise and network, we partner with visionary entrepreneurs to bring transformative solutions to the global market.
OpusOne™ is an investigational device, not yet approved for commercial use.
For more information, please contact:
media@enginprime.com; info@voyagerscap.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD
The legacy of the iconic Seagull 1963 evolves with the brand's first split-seconds complication, offering haute horology at an accessible price point as Seagull Watch accelerates its global strategy.
TIANJIN, China, Dec. 16, 2025 /PRNewswire/ -- Seagull Watch, a historic manufacturer with over seven decades of mechanical expertise, today announced the global debut of its highly anticipated the Seagull Rattrapante Chronograph Blue Dial Limited Edition, a timepiece that marries historical lineage with cutting-edge mechanical innovation. The launch coincides with a significant milestone for the brand: the inauguration of its global official website at en.seagullwatch.com, which went alive in August, 2025, underscoring Seagull's deepened commitment to its international clientele.
This new Seagull Rattrapante Limited Edition, or split-seconds chronograph, first showcased at 2025 Hong Kong Watch & Clock Fair — answers a growing call from global watch enthusiasts for sophisticated complications without the prohibitive cost. It establishes a new value benchmark in its category, solidifying Seagull's reputation for "accessible haute horology".
The First Impression: Seagull Rattrapante
The Seagull Rattrapante presents an eye-catching interpretation of the brand's first split-seconds chronograph. Its Grade 5 titanium case is complemented by a multi-layered layout featuring recessed subdials and a tachymeter scale, creating strong visual depth and clarity. The aerospace-grade titanium case provides outstanding corrosion resistance, lightweight comfort, and hypoallergenic properties.
An independent pusher at 10 o'clock controls the rattrapante hand, enabling intermediate lap timing and multi-event measurement—complications traditionally reserved for far higher-priced luxury timepieces. Despite its engineering complexity, the watch maintains a sleek and contemporary presence, weighing just 70 grams with a 42.5 mm case diameter and a 16 mm thickness.
Inside, the Rattrapante is powered by Seagull's new in-house ST1961-2 calibre, a manual-wound movement that highlights the brand's capabilities in high-end chronograph manufacture. The ST1961-2 is the direct evolution of the legendary ST19 series that powered the original Seagull 1963, the first aviation chronograph of modern China.
"The original ST19 movement laid the foundation for our chronograph legacy," said Li Jiaqi, the head of Seagull Innovation Team. "With the ST1961, we integrated a fully realized split-seconds mechanism—one of the most respected complications in watchmaking—making it as China's first developed rattrapante chronograph."
The Seagull Rattrapante Chronograph Blue Dial Limited Edition is now available in 500 pieces, priced at US$4,299, exclusively through the global online flagship site: en.seagullwatch.com.
A Brand with a Legacy, A Vision for the Future
Since 1955, Seagull Watch has been a leader in Asian mechanical watchmaking, manufacturing its own movements and developing complex mechanisms like tourbillons and perpetual calendars, also pioneering the "tri-complication" (tourbillon, minute repeater and perpetual calendar) in China watchmaking. The brand has become a symbol of the nation's progress in modern horology.
Seagull's leadership in innovation is reflected in its extensive intellectual property portfolio, which includes more than 1,170 authorized patents—among them 25 international patents.
It is also one of the few watchmakers worldwide with a fully vertically integrated manufacturing system, producing 11 movement series and over 200 movement variants that supply a significant share of the global mechanical watch industry. Among them, the ST19 series is especially well regarded by collectors around the world.
Recent appearances at events such as the 2025 Hong Kong Watch & Clock Fair and the 78th Cannes International Film Festival underscore the brand's growing global presence.
According to Xu Chuangyue (徐創越/George Xu), CEO of Tianjin Seagull Watch Group, Seagull has seen overseas revenue growth of 100% to 200% over the past three quarters, with finished watches (excluding movement sales) now accounting for approximately 10% of international business — demonstrating robust growth potential.
The launch of Seagull global official website marks an important step in enhancing customer access to authenticated Seagull watch products, warranty services, and after-sales support. As the brand expands, Seagull plans to further develop its local network of boutiques and service centers, bringing Eastern watchmaking craftsmanship to a broader worldwide audience.
About Seagull Watch:
Founded in 1955 as the Tianjin Watch Factory, Seagull Watch is one of Asia's most established mechanical watch manufacturers. The brand is known for its vertically integrated production capabilities, spanning movement engineering, component manufacturing, and full watch assembly. Celebrated for the iconic Seagull 1963 aviation chronograph and its expertise in high-complication horology, Seagull has become a leading representative of "Eastern craftsmanship meets mechanical mastery", earning a respected place among global mechanical watch enthusiasts and collectors.
Media Contacts:
Seagull Watch Official Website: en.seagullwatch.com
Seagull Watch Marketing Team
marketing@seagullwatch.com
Suri Su
Sugj_ho@seagullwatch.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Seagull Watch Unveils New Rattrapante Chronograph and Announces Global Official Website Launch
Seagull Watch Unveils New Rattrapante Chronograph and Announces Global Official Website Launch
